Illumina has appointed Elizabeth Brady to be vice president of global supply chain and Emily Winn-Deen to be vice president of diagnostics development.
Brady, who formerly was a VP of global supply chain at Boston Scientific, will run global sourcing, planning, logistics, and distribution operations. She holds a BSc in business analysis and business economics from Indiana University.
Winn-Deen previously was VP of genetics and oncology R&D at Cepheid, and she was involved in diagnostics at Roche Molecular Systems, Applera, Oncor, and Bayer Diagnostics. She holds a BA in chemistry from Lehigh University and a PhD in chemistry from Boston University.
Illumina has granted Brady an option to purchase 120,000 shares of Illumina's common stock, and Winn-Deen an option to buy 112,000 shares.
High Throughput Genomics said that Lee Hartwell and Timothy Yeatman have joined its scientific advisory board.
Hartwell is president and director of the Fred Hutchinson Cancer Research Center. Yeatman is executive vice president, co-founder, and chief scientific officer of M2Gen.
David Traylor has joined Headwaters as a managing director within its life sciences group.
Traylor previously worked at Caris & Company, where he was focused on capital formation for biopharmaceutical and device companies. He also previously led the management of programs at Affymetrix, and held senior business development positions at Atugen and BioSeek.
Traylor holds BA degrees from the University of Colorado Boulder in molecular and cellular biology and biochemistry and an MBA from the Leeds School of Business at the University of Colorado Boulder.